DOCSLIB.ORG

Status Ds Tca Pi-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Status Ds Tca Pi-1 References Symbols Key P-58109-F Principle 1. Fairlight Consulting. The Status DS TCA test uses solid-phase chromatographic http://www.fairlite.com/ocd/articles/ tricyclic.shtml DS membrane immunoassay technology for the qualitative Instructions For Use (Read) detection of tricyclic antidepressants. The test is based on 2. Bickel MH. Poisoning by Tricyclic Antidepressant the principle of the highly specific immunochemical Drugs. Int. J. Clinical Pharmacol. 11 (1975) 145-176 REF Item Number One-Step TCA Assay reactions between antigens and antibodies which are used (No. 2). For In Vitro Use Only for the analysis of specific substances in biological fluids. Store At The test relies on the competition between the drug 3. Baselt RC. Disposition of Toxic Drugs and Chemi- conjugates and the drugs which may be present in the urine cals in Man. 2nd ed., Davis, CA: Biomedical Simple One-Step Immunoassay for the Qualitative Detection of Tricyclic sample, for binding to antibodies. In the test procedure, a Publ.;1982;pp. 30-34, 223-225, 394-397, 568-571. Expiration Date sample of urine is placed in the Sample Well of the device Antidepressants in Urine and is allowed to migrate upward. If the drug is present in the CONT Contents urine sample, it competes with the drug conjugate bound to the dye, for the limited antibodies immobilized on the IFU Instructions For Use membrane. If the level of drug or drug metabolite is above the cutoff level, the drug will saturate the antibodies, thus inhibiting the binding of the dye coated with drug conjugates PIP Transfer Pipette LifeSign, LLC to the antibodies on the membrane. This prevents the formation of a line on the membrane. Therefore, a IVD For In Vitro Diagnostic Use Item No. 20910 10 Test Kit drug-positive urine sample will not generate a line at Test (T) Item No. 20935 35 Test Kit position in the Result Window, indicating a positive result LOT Lot Number from positive drug competition. A negative urine sample will generate a line at T position in the Result window, indicating Manufacturer a negative result from an absence of competition with free drugs.In addition to the Test line that may appear in the Result window, a Control line is present to confirm the MF Manufactured For viability of the test. This Control line (validation line) should Intended Use always appear if the test is conducted properly. Polyclonal EC REP Authorized Representative sheep anti-mouse IgG antibody is immobilized on the control Status DS TCA is a simple, one-step immuno- line. The monoclonal antibody-dye conjugates that pass the chromatographic assay for the rapid, qualitative detection of CE Mark line will be captured and produce a colored line at the tricyclic antidepressants (TCAs) . The test is standardized to Control position (C). This works as a procedural control, detect nortryptiline at a cutoff concentration of 1000 ng/mL in confirming that proper sample volume was used and the human urine. reagent system at the Control line and the conjugate-color The Status DS TCA test is a qualitative screening test, and indicator worked properly. If insufficient sample volume is provides only a preliminary analytical result. A negative result used, there may not be a Control line, indicating the test is does not eliminate the possibility of the presence of tricyclic invalid. antidepressants (TCAs) in the urine specimen at concentrations below the cutoff. A positive result may be due Materials Provided to the sum of the reactivities of more than one tricyclic The Status DS TCA test kit contains all the reagents antidepressant and/or their metabolites (see Table 2: necessary to perform the tests. Specificity). To obtain a confirmed analytical result, a more specific alternative method should be used, e.g., high • Status DS TCA device. The test device contains a performance liquid chromatography (HPLC) or gas membrane strip coated with polyclonal anti-nortryptiline chromatography, mass spectrometry (GC/MS). Clinical antibody and a pad containing drug-dye conjugate in a consideration and professional judgment should be applied protein matrix. to any drug test result, particularly when preliminary positive • Disposable specimen pipette. results are used. • Instructions for use. Summary and Explanation Precautions Tricyclic antidepressants (TCAs) are a type of prescription • For in vitro diagnostic use only. drug intended for clinically depressed patients. Unfortunately, they are becoming more frequently abused • Avoid cross contamination of urine samples by and are now one of the leading causes of death by drug using a new urine specimen container and pipette overdose in the United States. There are two broad chemical for each urine sample. classes of TCAs. The tertiary amines— amitryptiline, • The test kit does not contain any HIV or hepatitis imipramine, trimipramine and doxepin—boost serotonin infective components. levels and are prescribed for insomnia, irritability and overstimulation. The secondary amines—nortryptiline, • Urine specimens are potentially infectious. Proper desipramine and protryptiline—enhance nore- pinephrine handling and disposal methods should be levels and are prescribed for opposite types of symptoms, established according to good laboratory practices. such as excessive fatigue, withdrawal and inertness.1 Abuse • The Status DS device should remain in its original Printed in U.S.A. EC REP Manufactured by MF Manufactured for: of TCAs may lead to coma, respiratory depression, P-58109-F sealed pouch until ready for use. Do not use the test 232-9/13/12 MT Promedt Consulting GmbH convulsions, blood pressure deviations, hyperprexia and if the pouch is damaged or the seal is broken. Altenhofstrasse 80 severe cardiac conditions. TCAs are excreted in urine mostly 66386 St. Ingbert Princeton BioMeditech Corporation in the form of metabolites for up to ten days.2,3 • Do not use the test kit after the expiration date. Germany 4242 U.S. Hwy 1, Monmouth Jct. A PBM Group Company +49-68 94-58 10 20 New Jersey 08852, U.S.A. 85 Orchard Road, 1-732-274–1000 www.pbmc.com Skillman, NJ 08558 800-526-2125, 732-246-3366 www.lifesignmed.com 4 1 Storage and Stability Performance Characteristics The following compounds show no cross-reactivity when Invalid: A distinct Control line (C) should always appear. The tested with Status DS TCA at a concentration of 100 µg/mL The Status DS TCA test kit should be stored at 2–30°C test is invalid if no Control line forms at the C position. Such The Status DS TCA test has been shown to detect nortryptiline (Table 3). (35–86°F) in the original sealed pouch. The expiration dating tests should be repeated with a new Status DS test device. at an average cutoff of 1000 ng/mL in urine. The accuracy of was established under these storage conditions. There are other possible redults depending on the Status DS TCA was evaluated in comparison to commercially Table 3. Non Cross-Reacting Compounds: combination of drugs in the urine sample. available immunoassay, Triage®. A total of 203 samples was tested by both procedures. Complete agreement was 4-Acetamidophenol Meperidine Specimen Collection and Preparation observed in 99% of the samples as shown below (Table 1). Acetophenetidin Meprobamate Limitations (Phenacetin) Methadone Approximately 110 µL of urine sample is required for each N-Acetylprocainamide p-Hydroxymethamphetamine test. Fresh urine specimens do not require any special • If inadequate sample is dispensed into the sample well Table 1. Accuracy: Comparison of Status DS TCA with Acetylsalicylic acid Methaqualone handling or pretreatment. Specimens should be collected in (less than 3 full drops or 110 µL), the sample may not Triage® Aminopyrine Methoxyphenamine migrate in the device. Should no migration be observed Amitryptyline (±) 3,4-Methylenedioxyamphetamine a clean glass or plastic container. If testing will not be Triage® Amobarbital (±) 3,4-Methylenedioxymethamphetamine performed within 2 hours, specimens should be refrigerated within the first minute after addition of the sample, the user Amoxapine Methylphenidate may dispense another drop of the urine sample into the (2–8°C) for up to 48 hours. If longer storage is required, Positive Negative TOTAL Amoxicillin Methyprylon specimen may be stored frozen (-20°C or colder). Specimens device. This process may be repeated a second time. If D,L-Amphetamine Morphine-3-ß-Dglucuronide migration does not occur after the second sample addition Status DS Positive 103 2 105 l-Amphetamine Nalidixic acid should be brought to room temperature before testing. Apomorphine Nalorphine Specimens containing a large amount of particulate matter the test should be repeated with a new device. (TCA) Negative 0 98 98 Aspartame Naloxone may give inconsistent test results. Such specimens should TOTAL 103 100 203 Atropine Naltrexone be clarified by centrifuging or allowing to settle before • The test is designed for use with unadulterated urine only. Benzilic acid Naproxen Benzoic acid Niacinamide testing. Benzphetamine Nifedipine • There is a possibility that factors such as technical or Butabarbital Norcodein procedural errors, as well as other substances in the urine Precision and Accuracy Cannabidiol Norethindrone Test Procedure The test procedure consists of adding the urine sample to sample which are not listed in Table 3 below, may interfere The precision of the Status DS TCA assay was determined by Chloralhydrate Noroxymorphone with the test and cause erroneous results. Chloramphenicol D-Norpropoxyphene the Sample Well of the device and watching for the carrying out the test with serially diluted standard drug solu- Chlordiazepoxide (–) Norpseudoephedrine appearance of colored lines in the Result Window. tions. About 95% of the samples containing nortryptiline Chlorothiazide Noscapine • Adulterants, such as bleach and/or alum, in urine concentrations 25% over the cutoff level consistently Chlorpromazine Nylidrin specimens may produce erroneous results regardless of showed positive results. The study also included over 40 Chlorquine D,L-Octopamine Test Protocol the method of analysis.
Load more

Recommended publications
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • MDPV Bath Salts Test
    One Step Methylenedioxypyrovalerone Drug of Abuse Test MATERIALS Analytical Sensitivity The cut-off concentration of the One Step Methylenedioxypyrovalerone Drug of Abuse Test is determined to be 1,000ng/mL. (Dip Card) Materials Provided: Test was run in 30 replicates with negative urine and standard control at ±25% cut-off and ±50% cut-off concentration levels. Test results ● Dip cards are summarized below. For Forensic Use Only ● Desiccants ● Package insert Test Result INTENDED USE Percent of Cut-off n Materials Required But Not Provided: Methylenedioxypyrovalerone Concentration in ng/mL The One Step Methylenedioxypyrovalerone Drug of Abuse Test is a lateral flow chromatographic immunoassay for the ● Specimen collection container Negative Positive qualitative detection of Methylenedioxypyrovalerone (MDPV) in human urine specimen at the cut-off level of 1,000ng/mL. This ● Disposable gloves 0% Cut-off assay is intended for forensic use only. ● Timer 30 30 0 This assay provides only a preliminary qualitative test result. A more specific confirmatory reference method, such as Liquid (No Drug Present) chromatogra -50% Cut-off phy tandem mass spectrometry (LC/MS/MS) or gas chromatography/mass spectrometry (GC/MS) must be use in INSTRUCTIONS FOR USE] 30 30 0 order to obtain a confirmed analytical result. (500ng/mL) 1) Remove the dip card from the foil pouch. -25% Cut-off 30 30 0 BACKGROUND 2) Remove the cap from the dip card. Label the device with patient or control identifications. (750ng/mL) 3) Immerse the absorbent tip into the urine sample for 5 seconds. Urine sample should not touch the plastic device. Cut-off ‘Bath salts’, a form of designer drugs, also promoted as ‘plant food’ or ‘research chemicals’, is sold mainly in head shops, on 4) Replace the cap over the absorbent tip and lay the dip card on a clean, flat, and non-absorptive surface.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Octopamine and Tyramine Regulate the Activity of Reproductive Visceral Muscles in the Adult Female Blood-Feeding Bug, Rhodnius Prolixus Sam Hana* and Angela B
    © 2017. Published by The Company of Biologists Ltd | Journal of Experimental Biology (2017) 220, 1830-1836 doi:10.1242/jeb.156307 RESEARCH ARTICLE Octopamine and tyramine regulate the activity of reproductive visceral muscles in the adult female blood-feeding bug, Rhodnius prolixus Sam Hana* and Angela B. Lange ABSTRACT Monastirioti et al., 1996). Octopamine and tyramine signal via The role of octopamine and tyramine in regulating spontaneous G-protein coupled receptors (GPCRs), leading to changes in second contractions of reproductive tissues was examined in the messenger levels. The recently updated receptor classification α β female Rhodnius prolixus. Octopamine decreased the amplitude of (Farooqui, 2012) divides the receptors into Oct -R, Oct -Rs β β β spontaneous contractions of the oviducts and reduced RhoprFIRFa- (Oct 1-R, Oct 2-R, Oct 3-R), TYR1-R and TYR2-R. In general, β α induced contractions in a dose-dependent manner, whereas tyramine Oct -Rs lead to elevation of cAMP while Oct -R and TYR-Rs lead to 2+ only reduced the RhoprFIRFa-induced contractions. Both octopamine an increase in Ca (Farooqui, 2012). and tyramine decreased the frequency of spontaneous bursal The movement of eggs in the reproductive system of contractions and completely abolished the contractions at Rhodnius prolixus starts at the ovaries, the site of egg maturation. 5×10−7 mol l−1 and above. Phentolamine, an octopamine receptor Upon ovulation, mature eggs are released into the oviducts antagonist, attenuated the inhibition induced by octopamine on the (Wigglesworth, 1942). Eggs are then guided, via oviductal oviducts and the bursa. Octopamine also increased the levels of peristaltic and phasic contractions, to the common oviduct, where cAMP in the oviducts, and this effect was blocked by phentolamine.
    [Show full text]
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column
    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Can Hepatic Coma Be Caused by a Reduction of Brain Noradrenaline Or Dopamine?
    Gut: first published as 10.1136/gut.18.9.688 on 1 September 1977. Downloaded from Gut, 1977, 18, 688-691 Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine? L. ZIEVE AND R. L. OLSEN From the Department ofMedicine, Minneapolis Veterans Hospital, University of Minnesota, Minneapolis, and Department of Chemistry, Hamline University, St. Paul, Minnesota, USA SUMMARY Intraventricular infusions of octopamine which raised brain octopamine concentrations more than 20 000-fold resulted in reductions in brain noradrenaline and dopamine by as much as 90% without affecting the alertness or activity of normal rats. As this reduction of brain catechol- amines is much greater than any reported in hepatic coma, we do not believe that values observed in experimental hepatic failure have aetiological significance for the encephalopathy that ensues. Though catecholaminergic nerve terminals represent dopamine and noradrenaline had no discernible only a small proportion of brain synapses (Snyder et effect on the state of alertness of the animals. al., 1973), the reduction in brain dopamine or nor- adrenaline by the accumulation of false neuro- Methods transmitterssuch as octopamine or of aromaticamino acids such as phenylalanine or tyrosine has been ANIMALS suggested as a cause of hepatic coma (Fischer and Male Sprague-Dawley rats weighing between 300 and Baldessarini, 1971; Dodsworth et al., 1974; Fischer 350 were g prepared by the method of Peterson and http://gut.bmj.com/ and Baldessarini, 1975; Munro et al., 1975). The Sparber (1974) for intraventricular infusions of following data have been cited in support of this octopamine. Rats of 250-400 g were used as controls.
    [Show full text]
  • Comprehensive Panel, Blood
    COMPREHENSIVE PANEL, BLOOD Blood Specimens (Order Code 70510) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines Acetone Norbuprenorphine Gabapentin Brompheniramine Ethanol Nortramadol Lamotrigine Cetirizine Isopropanol Oxaprozin Levetiracetam Chlorpheniramine Methanol Pentoxifylline Methsuximide Cyclizine Amphetamines Phenacetin Phenytoin Diphenhydramine Amphetamine Phenylbutazone Pregabalin Doxylamine BDB Piroxicam Primidone Fexofenadine Benzphetamine Salicylic Acid* Topiramate Guaifenesin Ephedrine Sulindac* Zonisamide Hydroxyzine MDA Tapentadol Antidepressants Loratadine MDMA Tizanidine Amitriptyline Oxymetazoline* Mescaline* Tolmetin Amoxapine Pyrilamine Methcathinone Tramadol Bupropion Tetrahydrozoline Methamphetamine Anesthetics Citalopram Triprolidine Phentermine Benzocaine Clomipramine Antipsychotics PMA Bupivacaine Desipramine 9-hydroxyrisperidone Phenylpropanolamine Etomidate Desmethylclomipramine Aripiprazole Pseudoephedrine Ketamine Dosulepin Buspirone Analgesics Lidocaine Doxepin Chlorpromazine Acetaminophen Mepivacaine Duloxetine Clozapine Baclofen Methoxetamine Fluoxetine Fluphenazine Buprenorphine Midazolam Fluvoxamine Haloperidol Carisoprodol Norketamine Imipramine Mesoridazine Cyclobenzaprine Pramoxine* 1,3-chlorophenylpiperazine (mCPP) Norclozapine Diclofenac Procaine Mianserin* Olanzapine Etodolac Rocuronium Mirtazapine Perphenazine Fenoprofen Ropivacaine Nefazodone Pimozide Hydroxychloroquine Antibiotics Norclomipramine Prochlorperazine Ibuprofen Azithromycin* Nordoxepin Quetiapine Ketoprofen Chloramphenicol*
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]